FR2262533A2 - Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation - Google Patents

Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation

Info

Publication number
FR2262533A2
FR2262533A2 FR7406983A FR7406983A FR2262533A2 FR 2262533 A2 FR2262533 A2 FR 2262533A2 FR 7406983 A FR7406983 A FR 7406983A FR 7406983 A FR7406983 A FR 7406983A FR 2262533 A2 FR2262533 A2 FR 2262533A2
Authority
FR
France
Prior art keywords
culture
organism
centrifugation
pptn
prepn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7406983A
Other languages
English (en)
French (fr)
Other versions
FR2262533B2 (oth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to FR7406983A priority Critical patent/FR2262533A2/fr
Publication of FR2262533A2 publication Critical patent/FR2262533A2/fr
Application granted granted Critical
Publication of FR2262533B2 publication Critical patent/FR2262533B2/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR7406983A 1974-03-01 1974-03-01 Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation Granted FR2262533A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7406983A FR2262533A2 (en) 1974-03-01 1974-03-01 Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7406983A FR2262533A2 (en) 1974-03-01 1974-03-01 Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation

Publications (2)

Publication Number Publication Date
FR2262533A2 true FR2262533A2 (en) 1975-09-26
FR2262533B2 FR2262533B2 (oth) 1977-12-02

Family

ID=9135646

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7406983A Granted FR2262533A2 (en) 1974-03-01 1974-03-01 Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation

Country Status (1)

Country Link
FR (1) FR2262533A2 (oth)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2537725A1 (fr) * 1982-12-09 1984-06-15 Pasteur Institut Procede de detection immunobacteriologique de germes pathogenes dans des milieux biologiques contamines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2537725A1 (fr) * 1982-12-09 1984-06-15 Pasteur Institut Procede de detection immunobacteriologique de germes pathogenes dans des milieux biologiques contamines
EP0116793A1 (fr) * 1982-12-09 1984-08-29 INSTITUT PASTEUR Fondation reconnue d'utilité publique Procédé de détection immunobactériologique de germes pathogènes dans des milieux biologiques contaminés

Also Published As

Publication number Publication date
FR2262533B2 (oth) 1977-12-02

Similar Documents

Publication Publication Date Title
Mattos-Graner et al. Water-insoluble glucan synthesis by mutans streptococcal strains correlates with caries incidence in 12-to 30-month-old children
Fogg Extracellular products of algae in freshwater
Pollack et al. Exotoxin production by clinical isolates of Pseudomonas aeruginosa
DE3170913D1 (en) Vaccinal complex containing a specific antigen and vaccine containing it
AU5319794A (en) Method for obtaining a vaccine with wide protective range against group B neisseria meningitidis, the resulting vaccine, gammaglobulin and transfer factor
ATE5371T1 (de) Kosmetische mittel.
SE7708845L (sv) Framstellning av d(-)-3-hydroxismorsyra
EP0214340A3 (en) Process for detection of selected motile organisms
AU4695479A (en) Purified antigen
FR2262533A2 (en) Cholera vaccine prepn. - by lysing culture of the organism, or lysate, e.g. by pptn with trichloroacetic acid, then centrifugation
ES2078954T3 (es) Cepas bacterianas del genero bifidobacterium que tienen un potencial para induccion de iga.
Slack et al. Revision of serological grouping of Actinomyces
IE44448L (en) Gonococcal pili.
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
DE3263264D1 (en) Novel organism and use thereof in production of functionalized whey products
James et al. An improved method for the isolation of the major protein of the gonococcal outer membrane in an antigenically reactive form
Naito et al. The relationship between polysaccharide antigen and interleukin-1 beta producing activity in Porphyromonas gingivalis
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
WO2025226677A3 (en) Modified dna antibody constructs for use against pseudomonas aeruginosa
FR2388049A2 (fr) Procede de preparation de fractions antigeniques vaccinantes
Barakat et al. THE PROTECTIVE EFFECT OF VACCINATION WITH CORYNE BACTERIUM OVIS ON SHEEP POX INFECTION
JPS5718981A (en) Uk 788 strain
HRIB et al. THE MICROCHAMBER CULTIVATION OF ALGAE
Dzhevizov et al. Applied Microbiology in Non-Comminuted Meats. 2. Selection of Microbial Strains to Be Applied as Starters in the Manufacture of Non-Comminuted Meats.
Roe et al. DNA macromutant identified as flavobacterium total lack of immunologic relationship to flavobacterium